Copyright
©The Author(s) 2020.
World J Clin Cases. Dec 26, 2020; 8(24): 6264-6273
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Published online Dec 26, 2020. doi: 10.12998/wjcc.v8.i24.6264
Table 3 Comparison of viral-related factors between the hepatitis B virus reactivation group and the nonreactivation group
| Reactivation (n = 44) | Nonreactivation (n = 894) | P value | |
| HBcAb titer | 9.00 ± 0.45, 95%CI: 8.12-9.89 | 7.22 ± 0.100, 95%CI: 7.02-7.43 | < 0.0001 |
| HBsAb+ (%) | 59.0 | 67.8 | 0.1490 |
| HBsAb ≤ 10 (mIU/mL) (%) | 43.1 | 35.2 | 0.1785 |
| HBsAb titer | 395.5 | 473.1 | 0.059 |
| HBeAb+ (%) | 52.0 | 43.0 | 0.2540 |
| HCVAb+ (%) | 9.0 | 10.3 | 0.9417 |
- Citation: Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273
- URL: https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i24.6264